Jazz Pharmaceuticals plc provided earnings guidance for the full year 2024. For the period, the company expected revenues to be in the range of $4,000 million to $4,200 million, net income of $385 million to $530 million and net income per diluted share to be in the range of $5.80 to $7.70.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
109.5 USD | +1.89% | -0.44% | -11.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.01% | 6.82B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024